Prometrium Related Published Studies
Well-designed clinical trials related to Prometrium (Progesterone Oral)
Progesterone for premenstrual syndrome. [2012]
Physiological doses of progesterone potentiate the effects of triazolam in healthy, premenopausal women. [2011.06]
A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. [2011.05]
Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. [2011.05]
Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. [2011.03.01]
The effects of oral micronized progesterone on smoked cocaine self-administration in women. [2011.02]
Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal
progesterone receptor antagonist. [2011]
Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. [2010.09]
Effects of estrogen plus progesterone on hemodynamic and vascular reactivity in hypertensive postmenopausal women. [2010.06]
Efficacy of micronised vaginal progesterone versus oral dydrogestrone in the treatment of irregular dysfunctional uterine bleeding: a pilot randomised controlled trial. [2009.12]
Effects of nonoral estradiol-micronized progesterone or low-dose oral estradiol-drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause. [2009.08]
[Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis] [2009.07]
Oral micronized progesterone for prevention of preterm birth. [2009.01]
Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause. [2009]
Oral micronized progesterone for prevention of preterm birth. [2008.10.15]
Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. [2008.10]
Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users. [2008.09]
Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women. [2008.04]
Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. [2008]
The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors. [2008]
Progesterone effects on cocaine use in male cocaine users maintained on methadone: A randomized, double-blind, pilot study. [2007.10]
A comparative study of Cyclofem and depot medroxyprogesterone acetate (DMPA) effects on endometrial vasculature. [2007.10]
Effect of three doses of conjugated estrogens/medroxyprogesterone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study. [2007.08]
Effect of mifepristone on endometrial matrix metalloproteinase expression and leukocyte abundance in new medroxyprogesterone acetate users. [2007.07]
Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study. [2007.06]
Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. [2007.05]
Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. [2007.03]
Progesterone acutely increases LH pulse amplitude but does not acutely influence nocturnal LH pulse frequency slowing during the late follicular phase in women. [2007.03]
Mifepristone alters expression of endometrial steroid receptors and their cofactors in new users of medroxyprogesterone acetate. [2007.01]
[Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol] [2007]
Pharmacokinetics and safety of tanaproget, a nonsteroidal progesterone receptor agonist, in healthy women. [2006.11]
Associations of histories of depression and PMDD diagnosis with allopregnanolone concentrations following the oral administration of micronized progesterone. [2006.11]
Oral progesterone decreases saccadic eye velocity and increases sedation in women. [2006.11]
Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. [2006.10]
Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. [2006.10]
Allopregnanolone concentration and mood--a bimodal association in postmenopausal women treated with oral progesterone. [2006.08]
Diet-induced alterations in progesterone clearance appear to be mediated by insulin signaling in hepatocytes. [2006.05]
Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. [2006.03.20]
Comparison of two regimens of a monthly injectable contraceptive containing dihydroxyprogesterone acetophenide and estradiol enanthate. [2006.03]
The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. [2006.03]
Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. [2005.12]
Transdermal progesterone cream as an alternative progestin in hormone therapy. [2005.11]
Effect of oral conjugated equine estrogen combined with medroxyprogesterone acetate on plasma homocysteine levels in postmenopausal women. [2005.10]
Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study. [2005.09.16]
Concentration of depot medroxyprogesterone acetate and pain scores in adolescents: a randomized clinical trial. [2005.08]
Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product. [2005.06]
The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. [2005.04]
Effect of antiprogesterone mifepristone followed by misoprostol on circulating leptin in early pregnancy. [2005.02]
Estradiol and the addition of progesterone increase the sensitivity to a neurosteroid in postmenopausal women. [2005.01]
Effects of affiliation and power motivation arousal on salivary progesterone and testosterone. [2004.12]
The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a). [2004.11.15]
[A study of two different routes of administration of micronized progesterone in assisted reproduction] [2004.08]
Effects of progesterone treatment on cocaine responses in male and female cocaine users. [2004.08]
Effect of continuous administration of conjugated estrogen plus medroxyprogesterone acetate (Premelle) in postmenopausal women in Taiwan. [2004.07]
High-dose oral medroxyprogesterone acetate or tamoxifen as adjuvant hormone therapy for node-negative early-stage breast cancer: randomized trial with 7-year update. [2004.06]
Efficacy of oral micronized progesterone when applied via vaginal route. [2004.05]
Effects of oral and transdermal 17 beta-estradiol combined with progesterone on homocysteine metabolism in postmenopausal women: a randomised placebo-controlled trial. [2004.05]
Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women. [2004.03.15]
Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. [2003.11]
Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. [2003.09.01]
Inhibition of progesterone secretion by oestradiol administered in the luteal phase of assisted conception cycles. [2003.06]
Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human male. [2003.04]
Effect of medroxyprogesterone acetate on the efficiency of an oral protein-rich nutritional support in HIV-infected patients. [2003.03]
The early response of the postmenopausal endometrium to tamoxifen: expression of estrogen receptors, progesterone receptors, and Ki-67 antigen. [2003.03]
A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. [2003.01]
Vaginal micronized progesterone in continuous hormone replacement therapy. A prospective randomized study. [2002.12]
The effects of short-term medroxyprogesterone acetate and micronized progesterone on glucose metabolism and lipid profiles in patients with polycystic ovary syndrome: a prospective randomized study. [2002.10]
Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. [2002.06]
Simplified artificial endometrial preparation, using oral estradiol and novel vaginal progesterone tablets: a prospective randomized study. [2002.04]
Comparative endometrial histology in postmenopausal women with sequential hormone replacement therapy of estradiol and, either chlormadinone acetate or micronized progesterone. [2002.02.26]
Estrogen/progesterone replacement versus pravastatin and their sequential association in hypercholesterolemic postmenopausal women. [2001.12.14]
Delayed first injection of the once-a-month injectable contraceptive containing 25 mg medroxyprogesterone acetate and 5 mg estradiol-cypionate: effects on cervical mucus. [2001.12]
Natural vaginal progesterone is associated with minimal psychological side effects: a preliminary study. [2001.12]
Association of oral almitrine and medroxyprogesterone acetate: effect on arterial blood gases in chronic obstructive pulmonary disease. [2001.07]
Progesterone treatment during the early follicular phase of the menstrual cycle: effects on smoking behavior in women. [2001.05]
Oral 17beta-estradiol and medroxyprogesterone acetate therapy in postmenopausal women increases HDL particle size. [2001.04]
Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. [2000.12]
Quality of life assessment in patients with hormone-resistant prostate cancer treated with epirubicin or with epirubicin plus medroxy progesterone acetate - is it feasible? [2000.09]
Estrogen modifies the temperature effects of progesterone. [2000.05]
Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women(3). [2000.03]
A double-blind, randomized, comparative study evaluating clinical effects of two sequential estradiol-progestogen combinations containing either desogestrel or medroxyprogesterone acetate in climacteric women. [2000.02.15]
Estradiol/progesterone substitution in the luteal phase improves pregnancy rates in stimulated cycles--but only in younger women. [2000.01]
A prospective randomized study comparing intramuscular with intravaginal natural progesterone in programmed thaw cycles. [1999.10]
The role of low progesterone and tension as triggers of perimenstrual chocolate and sweets craving: some negative experimental evidence. [1999.09]
Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration. [1999.08]
The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. [1999.06.01]
Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. [1999.06]
Acute effect of alcohol on estradiol, estrone, progesterone, prolactin, cortisol, and luteinizing hormone in premenopausal women. [1999.06]
Bone density effects of continuous estrone sulfate and varying doses of medroxyprogesterone acetate. Ogen/Provera Study Group. [1999.06]
Influence of endogenous progesterone on alprazolam pharmacodynamics. [1999.06]
Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics. [1999.05]
Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. [1999.04]
A randomized controlled comparative study of oral medroxyprogesterone acetate 1,200 and 600 mg in patients with advanced or recurrent breast cancer. [1999]
[The effect of various methods of luteal phase supplementation on serum progesterone level] [1998.12]
Menopausal symptom control and side-effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate. Ogen/Provera Study Group. [1998.09]
Development of a progestin-based estrus synchronization program: II. Reproductive response of cows fed melengestrol acetate for 14 days with injections of progesterone and prostaglandin F2alpha. [1998.05]
Development of a progestin-based estrus synchronization program: I. Reproductive response of cows fed melengestrol acetate for 20 days with an injection of progesterone. [1998.05]
Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea. [1998.01]
Experience with a novel vaginal progesterone preparation in a donor oocyte program. [1998.01]
Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. [1997.11]
Peripheral progesterone (P) levels and endometrial response to various dosages of vaginally administered P in estrogen-primed women. [1997.11]
|
